DFTX Definium Therapeutics, Inc.
Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1813814 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-100.8%
TTM EPS YoY-47.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-61.4%
ROA-51.5%
ROIC (approx.)-43.9%
Asset turnover—
Leverage & solvency
Liabilities / assets9.9%
Debt / equity0.04x
Current ratio15.53x
Interest coverage-51.91x
Cash quality & payout
Operating cash flow / net income0.57x
Accruals ratio-22.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $46.14M | $48.66M | $41.48M | $33.52M | $30.98M | $29.81M | $23.36M | $21.76M |
| SG&A expense | $26.14M | $26.41M | $17.74M | $14.06M | $14.69M | $11.09M | $8.80M | $10.70M |
| Operating income | -$72.28M | -$75.08M | -$59.22M | -$47.58M | -$45.67M | -$40.90M | -$32.16M | -$32.46M |
| Interest expense | $1.15M | $1.23M | $1.25M | $1.27M | $1.27M | $2.34M | $602,000 | $656,000 |
| Net income | -$50.96M | -$158.99M | -$77.10M | -$50.44M | -$67.27M | -$42.74M | -$23.35M | -$34.74M |
| EPS (basic) | -0.37 | -1.44 | -0.71 | — | -0.78 | -0.50 | -0.27 | — |
| EPS (diluted) | -0.46 | -1.44 | -0.71 | — | -0.78 | -0.50 | -0.35 | — |
| Weighted avg. shares (diluted) | 137.35M | 110.68M | 108.79M | — | 85.89M | 85.35M | 87.09M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $241.15M | $655.27M | $262.52M | $257.84M | $19.96M | $33.39M | $82.85M | $273.74M |
| Short-term investments | $805.70M | $428.61M | $110.90M | $153.76M | $189.11M | $149.60M | $129.59M | $0 |
| Current assets | $1.05B | $1.09B | $380.56M | $419.32M | $215.85M | $189.14M | $221.70M | $281.62M |
| Goodwill | $19.92M | $19.92M | $19.92M | $19.92M | $19.92M | $19.92M | $19.92M | $19.92M |
| Intangibles | — | — | — | — | — | — | — | $0 |
| Total assets | $1.07B | $1.11B | $401.29M | $440.10M | $236.92M | $265.09M | $275.32M | $302.15M |
| Current liabilities | $67.73M | $157.20M | $81.11M | $66.70M | $65.42M | $37.96M | $30.48M | $38.85M |
| Long-term debt | $36.66M | $36.47M | $40.77M | $40.58M | $40.38M | $41.19M | $22.04M | $21.85M |
| Total debt | $36.66M | $36.47M | $40.77M | $40.58M | $40.38M | $41.19M | $22.04M | $21.85M |
| Total liabilities | $106.25M | $194.22M | $122.44M | $107.77M | $106.32M | $79.69M | $52.52M | $60.70M |
| Shareholders' equity | $968.03M | $918.68M | $278.85M | $332.33M | $130.60M | $185.40M | $222.81M | $241.45M |
| Net debt | -$204.49M | -$618.80M | -$221.75M | -$217.26M | $20.43M | $7.80M | -$60.82M | -$251.89M |
| Shares outstanding | 136.89M | 134.37M | 104.04M | 98.78M | 76.77M | 75.80M | 75.51M | 75.10M |
| Cash flow statement | ||||||||
| Operating cash flow | -$52.98M | -$52.78M | -$42.63M | -$42.98M | -$29.57M | -$29.60M | -$29.42M | -$25.35M |
| Investing cash flow | -$372.80M | -$316.74M | $42.00M | $34.98M | $15.41M | -$39.54M | -$162.46M | $0 |
| Financing cash flow | $11.66M | $762.27M | $5.31M | $245.87M | $749,000 | $19.65M | $1.00M | $3.81M |
| Stock-based compensation | $10.78M | $9.64M | $7.13M | $5.60M | $5.82M | $5.25M | $3.43M | $3.44M |
Free plan shows the latest 8 periods; Pro shows all 23 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.